Clinical Surgery
Precision Hemostasis Solutions
Chitosan achieves rapid hemostasis in ≤30 seconds through a physical cross-linking mechanism, independent of clotting factors. 95%+ success rate on anticoagulant patients. Fully degrades in 8-12 weeks with no removal surgery required.
Cascading Consequences of Hemostasis Material Failure
Hemostasis failure in the operating room is irreversible. The cost of choosing wrong is not money — it is patient safety and your professional reputation.
Uncontrolled Oozing in Anticoagulant Patients
Patients on warfarin or heparin render conventional hemostasis completely ineffective. Intraoperative blood loss increases by 40%, forcing extended surgical time.
Deep Wounds Require Second Surgery for Removal
Traditional non-degradable hemostatic materials packed in deep wounds require a second surgery for removal. Extended recovery and increased medical costs.
Exothermic Materials Burn Tissue
Zeolite-based hemostatic materials can raise wound temperatures, risking nerve tissue burns. When it happens, medical disputes are unavoidable.
Persistent Post-Operative Infection Rates
Wound infections lead to antibiotic escalation and prolonged hospitalization. Infection rates within 72 hours rise from 12%, increasing the medical burden.
Chitosan Physical Cross-linking Mechanism
Independent of clotting factors, effective for patients on anticoagulant drugs.
Positive Charge Adsorption
Chitosan molecules carry a natural positive charge, instantly attracting negatively charged red blood cells and platelets to form a cell-rich layer.
Physical Cross-linked Gel
Chitosan chains undergo physical cross-linking to form a dense gel seal, physically blocking bleeding points without relying on clotting factors.
8-12 Week Degradation
The gel seal gradually degrades into glucosamine (a natural body component) and is fully resorbed by tissue with no removal surgery needed.
Why the OR Chooses Chitosan
Independent of Clotting Factors
Physical cross-linking hemostasis mechanism, equally effective for patients on warfarin, heparin, and other anticoagulants. Clinically validated 95%+ hemostasis success rate.
Fully Degrades in 8-12 Weeks
Degradation product is glucosamine — no second surgery needed. Degradation cycle perfectly matches tissue healing rate.
Broad-Spectrum Antimicrobial ≥99%
Natural chitosan antimicrobial capability achieves ≥99% inhibition against S. aureus and E. coli. Post-operative infection rate drops from 12% to 2.3%.
Zero Exotherm — Tissue Safe
Hydration reaction produces zero exotherm, no wound temperature rise during surgery. 500+ clinical cases validated with zero material-related adverse events.
Specialized Hemostasis for High-Risk Surgery
Different procedures require different chitosan product forms — precisely matched to departmental needs
Cardiovascular Surgery
Effective Under AnticoagulationAnticoagulation under cardiopulmonary bypass challenges conventional hemostasis. Chitosan hemostatic powder maintains equal efficacy in heparinized patients.
Recommended: Chitosan Hemostatic Powder (Enhanced)Hepatobiliary Surgery
8-12 Week DegradationThe liver and spleen, as highly vascular organs, present persistent challenges. Chitosan hemostatic gauze swelling forms a dense gel seal. Degrades in 8-12 weeks.
Recommended: Chitosan Hemostatic GauzeNeurosurgery
Zero ExothermSpinal venous plexus bleeding demands precision. Chitosan hemostatic sponge can be cut to fit narrow surgical fields. Zero exotherm ensures no damage to neural tissue.
Recommended: Chitosan Hemostatic SpongeOrthopedic Surgery
Bone Surface HemostasisBone surface oozing in joint replacement is difficult to electrocauterize. Chitosan powder forms a gel seal in 30s without affecting cement or fixation.
Recommended: Chitosan Hemostatic PowderTrauma Surgery
Large Area WoundsPolytrauma patients have complex wounds and large oozing areas. Z-fold gauze allows rapid coverage of irregular wounds to control diffuse oozing.
Recommended: Chitosan Hemostatic GauzeMinimally Invasive
Deep Wound FillingLaparoscopic small incisions require deep hemostasis. Chitosan granules can be injected via Trocar to fill deep wounds without blocking visualization.
Recommended: Chitosan Hemostatic GranulesData-Driven Clinical Validation
Success Rate
Multicenter clinical data including anticoagulated patient groups, covering major procedures in CV, hepatobiliary, and neurosurgery.
Infection Rate
Chitosan reduces post-op infection rate to 2.3% compared to 12% with traditional materials, reducing antibiotic use.
Adverse Events
500+ clinical cases validated with zero material-related adverse event reports. Full ISO 10993 compliance.
Key Concerns for Surgeons
Is chitosan really effective for patients on anticoagulants?
Yes. Chitosan stops bleeding through a physical positive charge adsorption mechanism, completely independent of clotting factors. Clinical data shows a 95%+ success rate even in patients on warfarin or heparin.
Will it cause foreign body reactions during 8-12 week degradation?
No. Chitosan degrades into glucosamine, a natural component of human joint cartilage. ISO 10993 testing shows no cytotoxicity, sensitization, or irritation. Zero material-related adverse events in 500+ cases.
Is the antimicrobial effect permanent?
Chitosan's antibacterial properties remain effective throughout the material's residence (8-12 weeks). It achieves ≥99% inhibition against common pathogens, reducing post-op infection from 12% to 2.3%.
Can chitosan materials be trimmed during surgery?
Yes. Chitosan sponges and gauze can be cut to fit wound shapes. Powders and granules are ideal for filling irregular deep wounds. Trimming does not affect hemostatic efficacy.
Get Clinical Evaluation Samples Within 24 Hours
Submit hospital name and department. We will assign a medical representative to provide clinical data reports and free trial kits.